Pexelizumab, An Anti-C5 Complement Antibody for Primary Coronary Revascularization: A New Insight fr

• 作 者: Gen-MinLin;
• 机 构: Division of Cardiology Hualien-Armed Forces General Hospital Taiwan
• 出 处: 2011第三届心脏病学大会
• 发表日期: 2011年期

　　Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to reduce reperfusion injury after coronary revascularization in acute myocardial infarction and severe coronary artery disease had been approved in phase Ⅰ animal studies and further demonstrated clinical benefits in phase Ⅱ study: the COMMA trial and phase Ⅲ study: the PRIMOCABG trial.However, the negative results of pexelizumab were observed in the COMPLY trial and the APEX-AMI trial.